Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or more after diagnosis. Despite aggressive multimodal therapy, consisting mostly of a combination of surgery, radiother...

Full description

Bibliographic Details
Main Authors: Joshua R. D. Pearson, Stefania Cuzzubbo, Simon McArthur, Lindy G. Durrant, Jason Adhikaree, Chris J. Tinsley, A. Graham Pockley, Stephanie E. B. McArdle
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
GBM - Glioblastoma multiforme
immune escape
immunotherapy
combinatorial therapy
treatment
overview
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.582106/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.582106/full

Similar Items